Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.
Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.